• Something wrong with this record ?

Methotrexate impact on radiographic progression in biologic-treated rheumatoid arthritis under clinical remission: A case report on monozygotic Caucasian twins

T. Soukup, J. Nekvindova, M. Dosedel, J. Brtkova, J. Toms, D. Bastecka, P. Bradna, J. Vlcek, P. Pavek,

. 2016 ; 29 (4) : 790-795. [pub] 20161021

Language English Country England, Great Britain

Document type Case Reports, Letter

Persistent link   https://www.medvik.cz/link/bmc17023602

We describe Caucasian monozygotic twin brothers with rheumatoid arthritis (RA) and discuss influence of predictors to methotrexate (MTX) outcome treatment. Single nucleotide polymorphisms (SNPs) of the MTX metabolic pathways were genotyped. Twins have multiple mutations: a CC mutation of SNP 1298A>C in methylenetetrahydrofolate reductase (MTHFR) gene, CC mutations of three SNPs in the adenosine receptor gene ADORA2A (rs3761422_4217241T>C, rs2267076_4221164T>C, rs2236624_4226593T>C), and a heterozygous genotype in SNPs ATIC_rs2372536_347C>G, MTHFD1_rs2236225_1958G>A. These mutations are known to predict a worse outcome of MTX treatment. The twins had different lifestyles (alcohol drinking and smoking in Twin 1, regular coffee consumption in Twin 2), but a very similar clinical presentation of the outset of RA, radiographic scoring according to the Sharp/van der Heijde method with an almost identical antibodies presentation. The period of the patients before anti-TNFα treatment was characterized by unsuccessful per oral MTX pharmacotherapy in both cases (a low effect of MTX in Twin 1; an early discontinuation of MTX due to an adverse event in Twin 2). In both twins, the outcome of well-controlled anti-TNFα treatment (co-medication with MTX in Twin 1) for 10 years was expressed as low disease activity measured using composite index DAS28. It is interesting that Twin 2 had an unfavorable radiographic scoring after a 10-year follow-up than Twin 1 in spite of the comparable DAS28 in Twin 2 and smoking in Twin 1. In conclusion, co-medication of MTX with biologics may impact on RA radiographic progression despite predicted bad MTX outcome based on pharmacogenetic analysis.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17023602
003      
CZ-PrNML
005      
20170906110628.0
007      
ta
008      
170720s2016 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1177/0394632016674725 $2 doi
035    __
$a (PubMed)27770044
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Soukup, Tomas $u Charles University in Prague, Faculty of Medicine and University Hospital in Hradec Kralove, 2nd Department of Internal Medicine - Gastroenterology, Hradec Kralove, Czech Republic.
245    10
$a Methotrexate impact on radiographic progression in biologic-treated rheumatoid arthritis under clinical remission: A case report on monozygotic Caucasian twins / $c T. Soukup, J. Nekvindova, M. Dosedel, J. Brtkova, J. Toms, D. Bastecka, P. Bradna, J. Vlcek, P. Pavek,
520    9_
$a We describe Caucasian monozygotic twin brothers with rheumatoid arthritis (RA) and discuss influence of predictors to methotrexate (MTX) outcome treatment. Single nucleotide polymorphisms (SNPs) of the MTX metabolic pathways were genotyped. Twins have multiple mutations: a CC mutation of SNP 1298A>C in methylenetetrahydrofolate reductase (MTHFR) gene, CC mutations of three SNPs in the adenosine receptor gene ADORA2A (rs3761422_4217241T>C, rs2267076_4221164T>C, rs2236624_4226593T>C), and a heterozygous genotype in SNPs ATIC_rs2372536_347C>G, MTHFD1_rs2236225_1958G>A. These mutations are known to predict a worse outcome of MTX treatment. The twins had different lifestyles (alcohol drinking and smoking in Twin 1, regular coffee consumption in Twin 2), but a very similar clinical presentation of the outset of RA, radiographic scoring according to the Sharp/van der Heijde method with an almost identical antibodies presentation. The period of the patients before anti-TNFα treatment was characterized by unsuccessful per oral MTX pharmacotherapy in both cases (a low effect of MTX in Twin 1; an early discontinuation of MTX due to an adverse event in Twin 2). In both twins, the outcome of well-controlled anti-TNFα treatment (co-medication with MTX in Twin 1) for 10 years was expressed as low disease activity measured using composite index DAS28. It is interesting that Twin 2 had an unfavorable radiographic scoring after a 10-year follow-up than Twin 1 in spite of the comparable DAS28 in Twin 2 and smoking in Twin 1. In conclusion, co-medication of MTX with biologics may impact on RA radiographic progression despite predicted bad MTX outcome based on pharmacogenetic analysis.
650    _2
$a antirevmatika $x terapeutické užití $7 D018501
650    _2
$a revmatoidní artritida $x farmakoterapie $x genetika $x patologie $7 D001172
650    _2
$a biologické přípravky $x terapeutické užití $7 D001688
650    _2
$a progrese nemoci $7 D018450
650    _2
$a kombinovaná farmakoterapie $x metody $7 D004359
650    _2
$a běloši $x genetika $7 D044465
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a methotrexát $x terapeutické užití $7 D008727
650    _2
$a lidé středního věku $7 D008875
650    _2
$a jednonukleotidový polymorfismus $x genetika $7 D020641
650    _2
$a výsledek terapie $7 D016896
650    _2
$a dvojčata monozygotní $7 D014430
655    _2
$a kazuistiky $7 D002363
655    _2
$a dopisy $7 D016422
700    1_
$a Nekvindova, Jana $u Charles University in Prague, University Hospital in Hradec Kralove, Institute of Clinical Biochemistry and Diagnostics, Hradec Kralove, Czech Republic.
700    1_
$a Dosedel, Martin $u Charles University in Prague, Faculty of Pharmacy in Hradec Kralove, Department of Social and Clinical Pharmacy, Hradec Kralove, Czech Republic martin.dosedel@faf.cuni.cz.
700    1_
$a Brtkova, Jindra $u Charles University in Prague, Faculty of Medicine and University Hospital in Hradec Kralove, Department of Radiology, Czech Republic.
700    1_
$a Toms, Jan $u Charles University in Prague, Faculty of Medicine and University Hospital in Hradec Kralove, 2nd Department of Internal Medicine - Gastroenterology, Hradec Kralove, Czech Republic.
700    1_
$a Bastecka, Drahomira $u Charles University in Prague, Faculty of Medicine and University Hospital in Hradec Kralove, 2nd Department of Internal Medicine - Gastroenterology, Hradec Kralove, Czech Republic.
700    1_
$a Bradna, Petr $u Charles University in Prague, Faculty of Medicine and University Hospital in Hradec Kralove, 2nd Department of Internal Medicine - Gastroenterology, Hradec Kralove, Czech Republic.
700    1_
$a Vlcek, Jiri $u Charles University in Prague, Faculty of Pharmacy in Hradec Kralove, Department of Social and Clinical Pharmacy, Hradec Kralove, Czech Republic.
700    1_
$a Pavek, Petr $u Charles University in Prague, Faculty of Pharmacy in Hradec Kralove, Department of Pharmacology and Toxicology, Hradec Kralove, Czech Republic.
773    0_
$w MED00002332 $t International journal of immunopathology and pharmacology $x 2058-7384 $g Roč. 29, č. 4 (2016), s. 790-795
856    41
$u https://pubmed.ncbi.nlm.nih.gov/27770044 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20170720 $b ABA008
991    __
$a 20170906111226 $b ABA008
999    __
$a ok $b bmc $g 1239283 $s 984515
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 29 $c 4 $d 790-795 $e 20161021 $i 2058-7384 $m International journal of immunopathology and pharmacology $n Int. j. immunopathol. pharmacol. $x MED00002332
LZP    __
$a Pubmed-20170720

Find record

Citation metrics

Archiving options